Skip to content

Released Feb 6, 2025, before the open

10-Q filed Feb 6, 2025, 37 days after period end · 0001764013-25-000026

Q3 2025 · 10-Q
Revenue—
Net Income-$111.12MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.76N/M vs Q3 2024N/M vs Q2 2025
Operating Cash Flowderived-$100,391,000N/M
Free Cash Flowderived-$100,571,000N/M

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Net Income-$111.12M-$51.42M-$63.23M-$41.39M
EPS Diluted-$0.76-$0.36-$0.49-$0.36

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR